Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1991;17:480-484

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rhaleb, N. E.
Right arrow Articles by Regoli, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rhaleb, N. E.
Right arrow Articles by Regoli, D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*LOSARTAN POTASSIUM

Hypertension, Vol 17, 480-484, Copyright © 1991 by American Heart Association


ARTICLES

DuP 753 is a specific antagonist for the angiotensin receptor

NE Rhaleb, N Rouissi, F Nantel, P D'Orleans-Juste and D Regoli
Department of Pharmacology, Medical School University of Sherbrooke, Quebec, Canada.

2-n-Butyl-4-chloro-5-hydroxy-methyl-1-[(2'-(1H)-tetrazol-5-yl)biph enyl- 4- yl)methyl]imidazol potassium salt (DuP 753) is a nonpeptide angiotensin II receptor antagonist that inhibits the contractile effects of angiotensin II competitively and shows pA2 values of 8.27 on the rabbit aorta and jugular vein, 8.66 on the rat portal vein and stomach, 8.19 on the rat urinary bladder, and 8.36 on human colon, ileum, and urinary bladder. This agent (more than 10(-5) M) exhibits no agonistic activity and does not affect the contractile effects of norepinephrine, acetylcholine, bradykinin, desArg9-bradykinin, substance P, neurokinin A, neurokinin B, or bombesin in the various tissues. The present results demonstrate that DuP 753 is a potent nonpeptide antagonist with high affinity, specificity, and selectivity for the angiotensin receptor.


This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
Q. H. Chen and G. M. Toney
Responses to GABA-A receptor blockade in the hypothalamic PVN are attenuated by local AT1 receptor antagonism
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1231 - R1239.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Tagawa and R. A. L. Dampney
AT1 Receptors Mediate Excitatory Inputs to Rostral Ventrolateral Medulla Pressor Neurons From Hypothalamus
Hypertension, December 1, 1999; 34(6): 1301 - 1307.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Li, C. M. Ferrario, and K. B. Brosnihan

J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1065 - 1070.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
D. G Kiely, R. I Cargill, N. M Wheeldon, W. J Coutie, and B. J Lipworth
Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale
Cardiovasc Res, January 1, 1997; 33(1): 201 - 208.
[Abstract] [Full Text] [PDF]